Smart Design of Small‐Molecule Libraries: When Organic Synthesis Meets Cheminformatics

Synthetic chemists are always looking for new methods to maximize the diversity and complexity of small‐molecule libraries. Diversity‐oriented synthesis can give access to new chemotypes with high chemical diversity, exploiting complexity‐generating reactions and divergent approaches. However, there is a need for new tools to drive synthetic efforts towards unexplored and biologically relevant regions of chemical space. Because the number of publicly accessible biological data will increase in the years to come, cheminformatics can represent a real opportunity to develop better chemical libraries. This minireview focuses on novel cheminformatics approaches used to design molecular scaffolds, as well as to analyze their quality, giving a perspective of them in the field of chemical biology and drug discovery through some selected case studies.

[1]  Yanli Wang,et al.  PubChem BioAssay: 2014 update , 2013, Nucleic Acids Res..

[2]  Herbert Waldmann,et al.  Bioactivity-guided navigation of chemical space. , 2010, Accounts of chemical research.

[3]  Fabrizio Giordanetto,et al.  Macrocyclic drugs and clinical candidates: what can medicinal chemists learn from their properties? , 2014, Journal of medicinal chemistry.

[4]  R. Sarpong,et al.  Construction of Enantiopure Taxoid and Natural Product-like Scaffolds Using a C-C Bond Cleavage/Arylation Reaction. , 2015, Organic letters.

[5]  Derek S. Tan,et al.  Diversity-oriented synthesis: exploring the intersections between chemistry and biology , 2005, Nature chemical biology.

[6]  David R Spring,et al.  Diversity-oriented synthesis as a tool for the discovery of novel biologically active small molecules. , 2010, Nature communications.

[7]  John P. Overington,et al.  ChEMBL: a large-scale bioactivity database for drug discovery , 2011, Nucleic Acids Res..

[8]  Channa K. Hattotuwagama,et al.  Lead-oriented synthesis: a new opportunity for synthetic chemistry. , 2012, Angewandte Chemie.

[9]  Andrew J. Bannister,et al.  A Chemical Probe for the ATAD2 Bromodomain. , 2016, Angewandte Chemie.

[10]  Adam Nelson,et al.  A divergent synthetic approach to diverse molecular scaffolds: assessment of lead-likeness using LLAMA, an open-access computational tool. , 2016, Chemical communications.

[11]  Petra Schneider,et al.  Counting on natural products for drug design. , 2016, Nature chemistry.

[12]  R. Morgentin,et al.  Synthesis of sp(3)-rich scaffolds for molecular libraries through complexity-generating cascade reactions. , 2016, Organic & biomolecular chemistry.

[13]  Adam Nelson,et al.  Evaluating New Chemistry to Drive Molecular Discovery: Fit for Purpose? , 2016, Angewandte Chemie.

[14]  Jürgen Bajorath,et al.  Application of a New Scaffold Concept for Computational Target Deconvolution of Chemical Cancer Cell Line Screens , 2017, ACS omega.

[15]  David DeCaprio,et al.  Cheminformatics approaches to analyze diversity in compound screening libraries. , 2010, Current opinion in chemical biology.

[16]  J. Christoffers,et al.  Quaternary Stereocenters: Challenges and Solutions for Organic Synthesis , 2005 .

[17]  H. Waldmann,et al.  Discovery of inhibitors of the Wnt and Hedgehog signaling pathways through the catalytic enantioselective synthesis of an iridoid-inspired compound collection. , 2013, Angewandte Chemie.

[18]  A. Hopkins,et al.  Navigating chemical space for biology and medicine , 2004, Nature.

[19]  Jürgen Bajorath,et al.  Analog series-based scaffolds: computational design and exploration of a new type of molecular scaffolds for medicinal chemistry , 2016, Future science OA.

[20]  S. Knapp,et al.  Design of a Biased Potent Small Molecule Inhibitor of the Bromodomain and PHD Finger-Containing (BRPF) Proteins Suitable for Cellular and in Vivo Studies. , 2017, Journal of medicinal chemistry.

[21]  A. Trabocchi,et al.  Diversity-Oriented Synthesis and Chemoinformatic Analysis of the Molecular Diversity of sp3-Rich Morpholine Peptidomimetics , 2018, Front. Chem..

[22]  A. H. Lipkus,et al.  Structural Diversity of Organic Chemistry. a Scaffold Analysis of the Cas Registry , 2022 .

[23]  Stuart L. Schreiber,et al.  A small molecule that binds Hedgehog and blocks its signaling in human cells , 2009, Nature chemical biology.

[24]  S. Wetzel,et al.  Biologie‐orientierte Synthese (BIOS) , 2011 .

[25]  Suresh B. Singh,et al.  The use of spirocyclic scaffolds in drug discovery. , 2014, Bioorganic & medicinal chemistry letters.

[26]  R. Hicklin,et al.  Synthesis of complex and diverse compounds through ring distortion of abietic acid. , 2014, Angewandte Chemie.

[27]  Andrei K. Yudin,et al.  Macrocycles: lessons from the distant past, recent developments, and future directions , 2014, Chemical science.

[28]  José L Medina-Franco,et al.  Molecular Scaffold Analysis of Natural Products Databases in the Public Domain , 2012, Chemical biology & drug design.

[29]  Markus Hartenfeller,et al.  A Collection of Robust Organic Synthesis Reactions for In Silico Molecule Design , 2011, J. Chem. Inf. Model..

[30]  G. Bemis,et al.  The properties of known drugs. 1. Molecular frameworks. , 1996, Journal of medicinal chemistry.

[31]  H. Waldmann,et al.  A natural product inspired tetrahydropyran collection yields mitosis modulators that synergistically target CSE1L and tubulin. , 2013, Angewandte Chemie.

[32]  Oliver Koch,et al.  What Can We Learn from Bioactivity Data? Chemoinformatics Tools and Applications in Chemical Biology Research. , 2017, ACS chemical biology.

[33]  Jeremy L. Jenkins,et al.  Clustering and Rule-Based Classifications of Chemical Structures Evaluated in the Biological Activity Space , 2007, J. Chem. Inf. Model..

[34]  Santiago Vilar,et al.  Medicinal chemistry and the molecular operating environment (MOE): application of QSAR and molecular docking to drug discovery. , 2008, Current topics in medicinal chemistry.

[35]  K. Lam,et al.  Combinatorial chemistry in drug discovery. , 2017, Current opinion in chemical biology.

[36]  Karina Martinez-Mayorga,et al.  Balancing novelty with confined chemical space in modern drug discovery , 2014, Expert opinion on drug discovery.

[37]  A. Trabocchi,et al.  Diversity-Oriented Synthesis as a Tool for Chemical Genetics , 2014, Molecules.

[38]  A. Alexakis,et al.  Metal-catalyzed asymmetric conjugate addition reaction: formation of quaternary stereocenters. , 2010, Chemical communications.

[39]  R. Hicklin,et al.  A ring-distortion strategy to construct stereochemically complex and structurally diverse compounds from natural products. , 2013, Nature chemistry.

[40]  A. Trabocchi,et al.  Diversity-oriented synthesis of morpholine-containing molecular scaffolds. , 2009, Chemistry.

[41]  C. Vanderwal,et al.  Efficient access to the core of the Strychnos, Aspidosperma and Iboga alkaloids. A short synthesis of norfluorocurarine. , 2009, Journal of the American Chemical Society.

[42]  Adam Nelson,et al.  Synthesis and Demonstration of the Biological Relevance of sp3‐rich Scaffolds Distantly Related to Natural Product Frameworks , 2017, Chemistry.

[43]  B. E. Evans,et al.  Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists. , 1988, Journal of Medicinal Chemistry.

[44]  Thomas Kodadek,et al.  Quantitative comparison of the relative cell permeability of cyclic and linear peptides. , 2007, Chemistry & biology.

[45]  Stefan Wetzel,et al.  Interactive exploration of chemical space with Scaffold Hunter. , 2009, Nature chemical biology.

[46]  Peter Ertl,et al.  The graphical representation of ADME-related molecule properties for medicinal chemists. , 2011, Drug discovery today.

[47]  Stuart L. Schreiber,et al.  Chemical probes and drug leads from advances in synthetic planning and methodology , 2018, Nature Reviews Drug Discovery.

[48]  C. Swain,et al.  Spirocyclic NK(1) antagonists I: [4.5] and [5.5]-spiroketals. , 2002, Bioorganic & medicinal chemistry letters.

[49]  Andreas Bender,et al.  How Similar Are Similarity Searching Methods? A Principal Component Analysis of Molecular Descriptor Space , 2009, J. Chem. Inf. Model..

[50]  Matthew P Jacobson,et al.  Testing the conformational hypothesis of passive membrane permeability using synthetic cyclic peptide diastereomers. , 2006, Journal of the American Chemical Society.

[51]  Russ B Altman,et al.  Machine learning in chemoinformatics and drug discovery. , 2018, Drug discovery today.

[52]  Daniel J. Foley,et al.  Evaluierung neuer Reaktionen zur Steuerung der Wirkstoff-Forschung: ein Eignungstest , 2016 .

[53]  György M. Keserü,et al.  The influence of lead discovery strategies on the properties of drug candidates , 2009, Nature Reviews Drug Discovery.

[54]  H. Maehr Combinatorial chemistry in drug research from a new vantage point. , 1997, Bioorganic & medicinal chemistry.

[55]  David R Spring,et al.  Diversity-oriented synthesis: producing chemical tools for dissecting biology. , 2012, Chemical Society reviews.

[56]  Gisbert Schneider,et al.  Scaffold diversity of natural products: inspiration for combinatorial library design. , 2008, Natural product reports.

[57]  Prasanna Venkatraman Specificity in the interaction of natural products with their target proteins--a biochemical and structural insight. , 2010, Mini reviews in medicinal chemistry.

[58]  Sorel Muresan,et al.  ChemGPS-NP: tuned for navigation in biologically relevant chemical space. , 2006, Journal of natural products.

[59]  Stephen J Haggarty,et al.  Diversity-Oriented Synthesis as a Strategy for Fragment Evolution against GSK3β. , 2016, ACS medicinal chemistry letters.

[60]  W. Unsworth,et al.  Ring-Expansion Approach to Medium-Sized Lactams and Analysis of Their Medicinal Lead-Like Properties. , 2017, Chemistry.

[61]  S. Schreiber,et al.  Target-oriented and diversity-oriented organic synthesis in drug discovery. , 2000, Science.

[62]  Ross McGuire,et al.  Data-driven medicinal chemistry in the era of big data. , 2014, Drug discovery today.

[63]  Tudor I. Oprea,et al.  Is There a Difference between Leads and Drugs? A Historical Perspective , 2001, J. Chem. Inf. Comput. Sci..

[64]  Wolfgang H. B. Sauer,et al.  Molecular Shape Diversity of Combinatorial Libraries: A Prerequisite for Broad Bioactivity , 2003, J. Chem. Inf. Comput. Sci..

[65]  Stefan Wetzel,et al.  Cheminformatic Analysis of Natural Products and their Chemical Space , 2007 .

[66]  G. Müller,et al.  Medicinal chemistry of target family-directed masterkeys. , 2003, Drug discovery today.

[67]  Xu-dong Cao,et al.  Design and diversity-oriented synthesis of novel 1,4-thiazepan-3-ones fused with bioactive heterocyclic skeletons and evaluation of their antioxidant and cytotoxic activities. , 2012, Bioorganic & medicinal chemistry letters.

[68]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings , 1997 .

[69]  Stephen P. Hale,et al.  The exploration of macrocycles for drug discovery — an underexploited structural class , 2008, Nature Reviews Drug Discovery.

[70]  B. B. Mishra,et al.  Natural products: an evolving role in future drug discovery. , 2011, European journal of medicinal chemistry.

[71]  E. Barreiro,et al.  From nature to drug discovery: the indole scaffold as a 'privileged structure'. , 2009, Mini reviews in medicinal chemistry.

[72]  Hong-min Liu,et al.  Spirooxindoles: Promising scaffolds for anticancer agents. , 2015, European journal of medicinal chemistry.

[73]  Stefan Wetzel,et al.  Biology-oriented synthesis. , 2011, Angewandte Chemie.

[74]  D Rognan,et al.  Towards the Next Generation of Computational Chemogenomics Tools , 2013, Molecular informatics.

[75]  M. Hann Molecular obesity, potency and other addictions in drug discovery , 2011 .

[76]  J. Sánchez-Quesada,et al.  Design and Synthesis of Fsp(3)-Rich, Bis-Spirocyclic-Based Compound Libraries for Biological Screening. , 2016, ACS combinatorial science.

[77]  Christopher J. White,et al.  Contemporary strategies for peptide macrocyclization. , 2011, Nature chemistry.

[78]  C. Lipinski Lead- and drug-like compounds: the rule-of-five revolution. , 2004, Drug discovery today. Technologies.

[79]  Stefan Wetzel,et al.  Charting, navigating, and populating natural product chemical space for drug discovery. , 2012, Journal of medicinal chemistry.

[80]  E. Furfine,et al.  New, potent P1/P2-morpholinone-based HIV-protease inhibitors. , 2006, Bioorganic & medicinal chemistry letters.

[81]  Stuart L. Schreiber,et al.  Small molecules of different origins have distinct distributions of structural complexity that correlate with protein-binding profiles , 2010, Proceedings of the National Academy of Sciences.

[82]  W Patrick Walters,et al.  What do medicinal chemists actually make? A 50-year retrospective. , 2011, Journal of medicinal chemistry.

[83]  J. Bajorath,et al.  Charting Biologically Relevant Spirocyclic Compound Space. , 2017, Chemistry.

[84]  M. Congreve,et al.  A 'rule of three' for fragment-based lead discovery? , 2003, Drug discovery today.

[85]  Petra Schneider,et al.  Chemography of Natural Product Space , 2015, Planta Medica.

[86]  Herbert Waldmann,et al.  Biology-oriented synthesis: harnessing the power of evolution. , 2014, Journal of the American Chemical Society.

[87]  Gisbert Schneider,et al.  Nonlinear dimensionality reduction and mapping of compound libraries for drug discovery. , 2012, Journal of molecular graphics & modelling.

[88]  A. Nadin,et al.  Leitstruktur‐orientierte Synthese: eine Alternative für die Synthesechemie , 2012 .

[89]  Elisabet Gregori-Puigjané,et al.  Docking and Linking of Fragments To Discover Jumonji Histone Demethylase Inhibitors. , 2016, Journal of medicinal chemistry.

[90]  R. Sarpong,et al.  Selective C-C and C-H bond activation/cleavage of pinene derivatives: synthesis of enantiopure cyclohexenone scaffolds and mechanistic insights. , 2015, Journal of the American Chemical Society.

[91]  Emanuele Perola,et al.  An analysis of the binding efficiencies of drugs and their leads in successful drug discovery programs. , 2010, Journal of medicinal chemistry.

[92]  A. Trabocchi,et al.  Two-step one-pot synthesis of dihydropyrazinones as Xaa-Ser dipeptide isosteres through morpholine acetal rearrangement. , 2015, Organic & biomolecular chemistry.

[93]  É. Marsault,et al.  Macrocycles are great cycles: applications, opportunities, and challenges of synthetic macrocycles in drug discovery. , 2011, Journal of medicinal chemistry.

[94]  Zoya Titarenko,et al.  BioCores: identification of a drug/natural product-based privileged structural motif for small-molecule lead discovery , 2010, Molecular Diversity.

[95]  A. Trabocchi,et al.  Short synthesis of polyfunctional sp3-rich threonine-derived morpholine scaffolds. , 2017, Organic & biomolecular chemistry.